Long-Acting Cabotegravir plus Rilpivirine in People With HIV Aged ≥60 Years: Real-World Evidence From the RELATIVITY Cohort in the Context of Multimorbidity

Conference Reports for NATAP

IDSA
ID Week 2026
October 21-24
Washington, DC


Long-Acting Cabotegravir plus Rilpivirine in People With HIV Aged ≥60 Years: Real-World Evidence From the RELATIVITY Cohort in the Context of Multimorbidity

	IDSA 2026 Wash DC Oct 21-26